NKGen Biotech, Inc. Warrants
NKGNW
NKGNW was delisted on the 4th of March, 2025.
3 hedge funds and large institutions have $14.1K invested in NKGen Biotech, Inc. Warrants in 2025 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 23 closing their positions.
88% less funds holding
Funds holding: 26 → 3 (-23)
95% less capital invested
Capital invested by funds: $268K → $14.1K (-$254K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 23
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$71.3K |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$15.9K |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$15K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$14K |
| 5 |
Jane Street
New York
|
-$10K |
NKGNW Hedge Fund Activity: Q1 2025 in Review
3 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Warrants (NKGNW) for Q1 2025, worth a combined $14.1K — down 95% from $268K a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of NKGNW and 0 opened new positions — a net loss of 23 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was Magnetar Financial, exiting entirely with an estimated $71.3K sold.
- 3 institutional investors held NKGen Biotech, Inc. Warrants (NKGNW) as of Q1 2025, down from 26 in Q4 2024.
- Funds reported $14.1K of NKGen Biotech, Inc. Warrants stock for Q1 2025, down 95% quarter-over-quarter.
- 0 funds opened new NKGen Biotech, Inc. Warrants positions in Q1 2025 and 23 closed out, a net change of -23 holders.
- The largest NKGen Biotech, Inc. Warrants seller in Q1 2025 was Magnetar Financial, an estimated $71.3K sold.
Based on aggregated 13F filings for Q1 2025.